Tigatuzumab

• UNSPSC Description:

  Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer[1].

• Target Antigen:

  Apoptosis

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Apoptosis

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/tigatuzumab.html

• Purity:

  95.00

• Solubility:

  10 mM in DMSO

• Smiles:

  [Tigatuzumab]

• Molecular Weight:

  144.6 (kDa)

• References & Citations:

  [1]Yamamoto J, et al. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model. Cancer Lett. 2020 Nov 1;492:174-184.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Clinical Information:

  Phase 2

• CAS Number:

  918127-53-4